News

Scientists identify chromosomal instability as a novel predictive biomarker for cancer drug Avastin

10/10/2018

Following a recent publication in the leading cancer  journal Journal of Clinical Oncology RCSI and international collaborators within the ANGIOPREDICT research consortium have now  further revealed chromosomal instability  (where  whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients benefit most from the use of a key drug to treat colorectal cancer (Avastin). By predicting the patients that would not benefit from Avastin, individuals could be spared the side-effects of this particular drug therapy, and are more likely to receive an optimal treatment with a minimum of delay, while reducing cost of care.

Scientists create a complete atlas of lung tumor cells

09/07/2018

Researchers from VIB, Leuven University and University Hospital Leuven studied thousands of healthy and cancerous lung cells to create the first comprehensive atlas of lung tumor cells. Their results reveal that tumors are much more complex than previously appreciated, distinguishing 52 different types of cells. This new information can be used to identify new research lines for treatment. The results of the study will be published in the leading journal Nature Medicine.

VIB pushes the boundaries of science to develop new diagnostic tools

27/07/2017

​Greater knowledge of molecular mechanisms and novel bio-analytical methods lead to more efficient and accurate diagnostics. With their world-leading strengths in molecular research and biotechnology, various VIB labs are paving the way for novel diagnostic tools that will ultimately reduce disease burden and save lives by making disease diagnosis better, faster and more flexible. The proof is in the partnership: three recent collaborations between VIB, university hospitals and diagnostics industry leaders highlight just how critical molecular science at VIB is to the development of cutting-edge diagnostic technology.